1 completed, 1 not yet recruiting, 1 recruiting, 1 unknown. 3 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Recruiting 1 |
| Not applicable | 1 | Unknown 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Amyloid Plaque: new trials by email Literature Review of Amyloid Plaque trials Research Report on Amyloid Plaque
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment Lenalidomide 10 mg - Cognitive Impairment, Mild, Cognitive Dysfunction | Phase 2 | Not yet recruiting | St. Joseph's Hospital and Medical Center, Phoenix | 45 | 2025-06-01 | 2025-05-18 |
| A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study) Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a - Amyloid Plaque, Beta-Amyloid | Phase 1 / Phase 2 | Recruiting | AC Immune SA | 304 | 2022-06-21 | 2026-07-10 |
| CLearing Alzheimer's Disease Molecular Pathology Without Medications 40 Hz multi-sensory (auditory + visual) stimulation and cognitive training, Cognitive training - Alzheimer Disease, Amyloid Plaque | Not applicable | Unknown | University Hospital, Geneva | 20 | 2021-08-01 | 2021-06-04 |
| MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients Lenalidomide 10 mg, Placebo - Cognitive Impairment, Mild, Cognitive Dysfunction | Phase 2 | Completed | St. Joseph's Hospital and Medical Center, Phoenix | 15 | 2020-07-22 | 2026-06-10 |
Alzheimer Disease (4) · Plaque, Amyloid (4) · Cognitive Dysfunction (2) · Encephalitis (2) · Amyloidosis (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Down Syndrome (1) · Heredodegenerative Disorders, Nervous System (1) · Memory Disorders (1) · Nerve Degeneration (1)
Mental Disorders (4) · Nervous System Diseases (4) · Neurocognitive Disorders (4) · Neurodegenerative Diseases (4) · Pathological Conditions, Anatomical (4) · Pathological Conditions, Signs and Symptoms (4) · Tauopathies (4) · Brain Diseases (3) · Central Nervous System Diseases (3) · Dementia (3) · Cognition Disorders (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Neurobehavioral Manifestations (2) · Neuroinflammatory Diseases (2)
Lenalidomide (2) · Cognitive Training (1)
St. Joseph's Hospital and Medical Center, Phoenix (2) · AC Immune SA (1) · University Hospital, Geneva (1)
United States (2) · Spain (1) · United Kingdom (1)
Boris Decourt, PhD (1) · Marwan N Sabbagh, M.D. (1) · Michael Rafii, MD (1)
K01AG047279 (1), R01AG059008 (1)